Bispecific t cell engagers for the treatment of multiple myeloma: Achievements and challenges

Kinan Alhallak, Jennifer Sun, Amanda Jeske, Chaelee Park, Jessica Yavner, Hannah Bash, Berit Lubben, Ola Adebayo, Ayah Khaskiah, Abdel Kareem Azab

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations

Abstract

MM is the second most common hematological malignancy and represents approximately 20% of deaths from hematopoietic cancers. The advent of novel agents has changed the therapeutic landscape of MM treatment; however, MM remains incurable. T cell-based immunotherapy such as BTCEs is a promising modality for the treatment of MM. This review article discusses the advancements and future directions of BTCE treatments for MM.

Original languageEnglish (US)
Article number2853
JournalCancers
Volume13
Issue number12
DOIs
StatePublished - Jun 2 2021
Externally publishedYes

Keywords

  • Bispecific T cell engagers
  • Chimeric antigen receptor-T cells
  • Multiple myeloma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Bispecific t cell engagers for the treatment of multiple myeloma: Achievements and challenges'. Together they form a unique fingerprint.

Cite this